News & Updates

VANCOUVER, Canada – SOLVE FSHD today announced new nonclinical data supporting SFH-4090 for the treatment of facioscapulohumeral muscular dystrophy (FSHD). The data were presented at the 31st Annual Congress of the World Muscle Society (WMS). SFH-4090, also known as MT-4090, discovered by Tanabe Pharma Corporation (Head Office: Osaka, Japan; Representative Director, CEO: Akihisa Harada), is …

ABINGTON, Mass. and VANCOUVER, BC, July 30, 2026 /PRNewswire/ — The FSHD Society, SOLVE FSHD, and the FSHD Clinical Trial Research Network (FSHD CTRN) today announced significant momentum for the FSHD Industry Collaborative, including the addition of four new biopharma sponsors and meaningful early progress across all active research workstreams. Launched in April 2026, the …

The FSHD Industry Collaborative is a first-of-its-kind, multi-stakeholder initiative designed to improve how FSHD clinical trials are designed, executed, and evaluated RANDOLPH, Mass. and VANCOUVER, BC, April 8, 2026 /PRNewswire/ — The FSHD Society, a patient-driven organization advancing research and clinical development in facioscapulohumeral muscular dystrophy (FSHD), SOLVE FSHD, a venture philanthropic organization dedicated to accelerating treatments …

VANCOUVER, British Columbia–(BUSINESS WIRE)–SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), today announced grant funding awarded following its 2025 Request for Proposals. SOLVE FSHD will provide funding to leading clinician scientists validating biomarker assays and clinical outcome frameworks in FSHD, with the intent to share the results with the …

Vancouver, BC & Tokyo & Waltham, Mass. – SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; “Modalis”), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting …

Vancouver, British Columbia and Columbus, Ohio, May 6, 2025 — SOLVE FSHD, a venture philanthropy organization committed to accelerating therapies for facioscapulohumeral muscular dystrophy (FSHD), today announced a $3 million investment in Armatus Bio, a biotechnology company developing next-generation vectorized RNAi therapeutics for neuromuscular diseases. The investment will support ARM-201, Armatus Bio’s AAV-delivered microRNA therapy …

Vancouver, BC, March 25, 2025 – SOLVE FSHD, a venture philanthropic organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), is pleased to announce a strategic collaboration with Transcripta Bio, a cutting-edge AI-driven drug discovery company. This collaboration will focus on leveraging Transcripta Bio’s advanced drug screening platform to identify and develop promising therapeutic candidates …

Vancouver, BC, December 5, 2024 – SOLVE FSHD, a venture philanthropy organization dedicated to catalyzing innovation and overcoming barriers to accelerate new therapies for facioscapulohumeral muscular dystrophy (FSHD), is calling on innovators worldwide to compete for the USD$10 million FSHD Bonus Prize, part of the XPRIZE Healthspan Competition launched on November 29, 2023. As part of …